文献速递肝病

衣壳组装调节剂NVR 3-778在慢性乙型肝炎感染者中的抗病毒活性、安全性与药代动力学

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
PubMed 文献 · Gastroenterology · 2019-01-06

本研究为1期试验,纳入73例无肝硬化的HBeAg阳性慢性HBV感染者,随机接受口服NVR 3-778(每日100、200、400 mg或每日两次600、1000 mg)或安慰剂治疗4周,另设联合聚乙二醇干扰素组。结果显示,NVR 3-778联合pegIFN组HBV DNA和HBV RNA平均下降幅度最大,HBsAg无显著下降,未出现停药及剂量相关不良事件模式,药物耐受性良好并显示抗病毒活性。

要点

  • NVR 3-778联合pegIFN组HBV DNA平均下降1.97 log10 IU/mL,高于单用NVR 3-778的1.43和单用pegIFN的1.06。
  • NVR 3-778联合pegIFN组HBV RNA平均下降2.09 log10 copies/mL,高于单用NVR 3-778的1.42和单用pegIFN的0.89。
  • 4周治疗期间HBsAg无显著平均下降,未出现停药及剂量相关不良事件模式。

核心结论

  • 在无肝硬化的HBeAg阳性慢性HBV感染者1期研究中,NVR 3-778耐受性良好并显示抗病毒活性。
  • NVR 3-778可降低血清HBV DNA和HBV RNA水平,与pegIFN联合时降低幅度最大。
  • 观察到的HBV RNA下降证实了NVR 3-778的新作用机制。

研究设计与样本

  • 1期研究,纳入73例无肝硬化的HBeAg阳性慢性HBV感染者。
  • 研究分两部分,第1部分在新西兰,第2部分在香港、新加坡、台湾、韩国和美国开展。
  • 患者随机接受口服NVR 3-778(每日100 mg、200 mg、400 mg或每日两次600 mg、1000 mg)或安慰剂治疗4周。
  • 另设联合治疗组接受pegIFN联合NVR 3-778(600 mg每日两次)或pegIFN联合安慰剂。

主要发现

  • 接受NVR 3-778每日≥1200 mg的患者中观察到血清HBV DNA和HBV RNA水平下降。
  • HBV DNA平均下降幅度:NVR 3-778联合pegIFN组1.97 log10 IU/mL,单用NVR 3-778组1.43 log10 IU/mL,单用pegIFN组1.06 log10 IU/mL。
  • HBV RNA平均下降幅度:NVR 3-778联合pegIFN组2.09 log10 copies/mL,单用NVR 3-778组1.42 log10 copies/mL,单用pegIFN组0.89 log10 copies/mL。
  • 4周治疗期间HBsAg无显著平均下降。
  • 未出现停药,未观察到NVR 3-778剂量相关不良事件模式。

关键数值与推荐

  • NVR 3-778给药方案包括每日100 mg、200 mg、400 mg或每日两次600 mg、1000 mg,疗程4周。
  • 联合治疗组NVR 3-778剂量为600 mg每日两次。
  • HBsAg在4周治疗期间无显著平均下降。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: NVR 3-778 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that can inhibit HBV replication. We performed a proof-of-concept study to examine the safety, pharmacokinetics, and antiviral activity of NVR 3-778 in patients with chronic HBV infection. METHODS: We performed a phase 1 study in 73 hepatitis B envelope antigen (HBeAg)-positive patients with chronic HBV infection without cirrhosis. In a 2-part study (part 1 in New Zealand and part 2 in Hong Kong, Singapore, Taiwan, Korea, and the United States), patients were randomly assigned to groups that were given oral NVR 3-778 (100 mg, 200 mg, or 400 mg daily or 600 mg or 1000 mg twice daily) or placebo for 4 weeks. Additional groups received combination treatment with pegylated interferon (pegIFN) and NVR 3-778 (600 mg twice daily) or pegIFN with placebo. RESULTS: Reductions in serum levels of HBV DNA and HBV RNA were observed in patients receiving ≥1200 mg/d NVR 3-778. The largest mean reduction in HBV DNA was observed in the group given NVR 3-778 plus pegIFN (1.97 log10 IU/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.43 log10 IU/mL and 1.06 log10 IU/mL, respectively). The mean reduction in HBV RNA was also greatest in the group given NVR 3-778 plus pegIFN (2.09 log10 copies/mL), compared with the groups given NVR 3-778 or pegIFN alone (1.42 log10 copies/mL and 0.89 log10 copies/mL, respectively). There was no significant mean reduction in HBsAg during the 4-week treatment period. There were no discontinuations and no pattern of dose-related adverse effects with NVR 3-778. CONCLUSIONS: In a phase 1 study of HBeAg-positive patients with chronic HBV infection without cirrhosis, NVR 3-778 was well tolerated and demonstrated antiviral activity. The agent reduced serum levels of HBV DNA and HBV RNA, to the greatest extent in combination with pegIFN. The observed reductions in HBV RNA confirmed the novel mechanism of NVR 3-778. Clinicaltrials.gov no. NCT02112799 (single-center) and NCT02401737 (multicenter).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Yuen MF, Gane EJ, Kim DJ, et al. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology. 2019. PMID: 30625297. doi:10.1053/j.gastro.2018.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。